Patents Assigned to Clinuvel Pharmaceuticals Limited
  • Therapy for vitiligo
    Patent number: 11622994
    Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: April 11, 2023
    Assignee: CLINUVEL PHARMACEUTICALS LIMITED
    Inventor: Philippe Wolgen
  • Methods of inducing melanogenesis in a subject
    Patent number: 10857208
    Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: December 8, 2020
    Assignee: CLINUVEL PHARMACEUTICALS LIMITED
    Inventors: Michael John Kleinig, Thomas R. Tice, Jay K. Staas
  • METHODS OF INDUCING MELANOGENESIS IN A SUBJECT
    Publication number: 20180360919
    Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Applicant: Clinuvel Pharmaceuticals Limited
    Inventors: Michael John KLEINIG, Thomas R. TICE, Jay K. STAAS
  • Methods of inducing melanogenesis in a subject
    Patent number: 10076555
    Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: September 18, 2018
    Assignee: Clinuvel Pharmaceuticals Limited
    Inventors: Michael John Kleinig, Thomas R. Tice, Jay K. Staas
  • Therapy for vitiligo
    Patent number: 9801924
    Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analog either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 31, 2017
    Assignee: Clinuvel Pharmaceuticals Limited
    Inventor: Philippe Wolgen
  • METHODS OF INDUCING MELANOGENESIS IN A SUBJECT
    Publication number: 20160235819
    Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 18, 2016
    Applicant: Clinuvel Pharmaceuticals Limited
    Inventors: Michael John KLEINIG, Thomas R. TICE, Jay K. STAAS
  • Methods of inducing melanogenesis in a subject
    Patent number: 9345911
    Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: May 24, 2016
    Assignee: Clinuvel Pharmaceuticals Limited
    Inventors: Michael John Kleinig, Thomas R. Tice, Jay K. Staas
  • Compositions and methods for including melanogenesis in a subject
    Patent number: 8569234
    Abstract: Described herein are compositions comprising an alpha-MSH analogue and a transdermal delivery system and methods for inducing melanogenesis and/or preventing UV radiation-induced skin damage in a subject by topical administration of these compositions.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: October 29, 2013
    Assignee: Clinuvel Pharmaceuticals Limited
    Inventors: Michael John Kleinig, Kenneth B. Kirby, Berno I. Pettersson, Jr.
  • Therapy For Vitiligo
    Publication number: 20130203670
    Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
    Type: Application
    Filed: March 13, 2013
    Publication date: August 8, 2013
    Applicant: CLINUVEL PHARMACEUTICALS LIMITED
    Inventor: Clinuvel Pharmaceuticals Limited
  • Method of treatment of photodermatoses
    Patent number: 8334265
    Abstract: This invention relates to a method for prophylactic or therapeutic treatment of photodermatoses that are caused or exacerbated by or associated with UVR exposure in a subject, particularly a human subject, which comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to reduce the photosensitivity of the skin of the subject.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: December 18, 2012
    Assignee: Clinuvel Pharmaceuticals Limited
    Inventor: Philippe Wolgen
  • Compositions and methods for including melanogenesis in a subject
    Publication number: 20110263508
    Abstract: Described herein are compositions comprising an alpha-MSH analogue and a transdermal delivery system and methods for inducing melanogenesis and/or preventing UV radiation-induced skin damage in a subject by topical administration of these compositions.
    Type: Application
    Filed: October 7, 2005
    Publication date: October 27, 2011
    Applicant: Clinuvel Pharmaceuticals Limited
    Inventors: Michael John Kleinig, Kenneth B. Kirby, Berno I. Pettersson, JR.
  • THERAPY FOR VITILIGO
    Publication number: 20110130705
    Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
    Type: Application
    Filed: March 27, 2009
    Publication date: June 2, 2011
    Applicant: Clinuvel Pharmaceuticals Limited
    Inventor: Philippe Wolgen
  • Method of inducing melanogenesis in humans with MC1R variant alleles
    Patent number: 7745408
    Abstract: A method for inducing melanogenesis in a human subject having a melanocortin 1 receptor (MC1R) variant allele associated with loss of or diminished receptor function comprises administering to said subject an amount of an ?-melanocyte stimulating hormone (?-MSH) analogue effective to induce melanogenesis by the melanocytes in the skin or other epidermal tissue of the subject.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: June 29, 2010
    Assignee: Clinuvel Pharmaceuticals Limited
    Inventor: Stuart Michael Humphrey
  • METHOD FOR REDUCING INCIDENCE OR RATE OF DEVELOPMENT OF SKIN CANCERS AND RELATED CONDITIONS
    Publication number: 20100113337
    Abstract: A method for treatment to reduce the incidence or rate of development of skin cancers and related conditions caused by or exacerbated by or associated with UVR-induced skin damage in an immuno-compromised subject, such as an organ transplant patient, comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to protect the skin of the subject from UVR-induced skin damage.
    Type: Application
    Filed: August 28, 2007
    Publication date: May 6, 2010
    Applicant: Clinuvel Pharmaceuticals Limited
    Inventor: Philippe Wolgen
  • Methods of Inducing Melanogenesis in a Subject
    Publication number: 20080305152
    Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
    Type: Application
    Filed: February 11, 2005
    Publication date: December 11, 2008
    Applicant: CLINUVEL PHARMACEUTICALS LIMITED
    Inventors: Michael John Kleinig, Thomas R. Tice, Jay K. Staas
  • Method of Inducing Melanogenesis in Humans With Mc1R Variant Alleles
    Publication number: 20080004213
    Abstract: A method for inducing melanogenesis in a human subject having a melanocortin 1 receptor (MC1R) variant allele associated with loss of or diminished receptor function comprises administering to said subject an amount of an ?-melanocyte stimulating hormone (?-MSH) analogue effective to induce melanogenesis by the melanocytes in the skin or other epidermal tissue of the subject.
    Type: Application
    Filed: November 23, 2004
    Publication date: January 3, 2008
    Applicant: Clinuvel Pharmaceuticals Limited
    Inventor: Stuart Humphrey